High Expression of MicroRNA-183/182/96 Cluster As a Prognostic Biomarker for Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2016 Apr 14

PMID 27071841

Citations 30

Authors

Cailu Song

Lijuan Zhang

Jin Wang

Zhongying Huang

Xing Li

Mingqing Wu

Shuaijie Li

Hailin Tang

Xiaoming Xie

Affiliations

Soon will be listed here.

Abstract

More sensitive and effective diagnostic markers for the detection of breast cancer are urgently needed. The microRNA-183/182/96 cluster has been reported to be involved in tumorigenesis and progression in a variety of cancers, and it is a promising cancer prognostic biomarker. The goal of this study was to determine the expression levels of the miR-183/182/96 cluster in breast cancer tissues and evaluate its prognostic role in breast cancer. Real-time quantitative polymerase chain reaction analysis (qRT-PCR) was used to detect the expression levels of the miR-183/182/96 cluster in 41 breast cancer tissues and adjacent normal tissues (control tissues) and also in different mammary cell lines. In situ hybridization (ISH) of the miR-183/182/96 cluster on 131 tissue microarrays (TMAs) was used to statistically analyze its prognostic role. The miR-183/182/96 cluster levels were significantly higher in breast cancer tissues than in control tissues. The miR-183/182/96 cluster was also upregulated in human breast cancer cell lines. An increased miR-183/182/96 cluster level was correlated with local relapse, distant metastasis and poor clinical outcomes. Our findings improve our understanding of the expression level of the miR-183/182/96 cluster in breast cancer and clarify the role of the miR-183/182/96 cluster as a novel prognostic biomarker for breast cancer.

Citing Articles

Integrated miRNA Signatures: Advancing Breast Cancer Diagnosis and Prognosis.

Samara M, Thodou E, Patoulioti M, Poultsidi A, Thomopoulou G, Giakountis A Biomolecules. 2024; 14(11).

PMID: 39595529 PMC: 11591846. DOI: 10.3390/biom14111352.

Investigating the interplay between the mir-183/182/96 cluster and the adherens junction pathway in early-stage breast cancer.

Noun T, Kurdi A, Maatouk N, Talhouk R, Dohna H Sci Rep. 2024; 14(1):24711.

PMID: 39433788 PMC: 11494207. DOI: 10.1038/s41598-024-73632-0.

The Overexpressed MicroRNAs miRs-182, 155, 493, 454, and U6 snRNA and Underexpressed let-7c, miR-328, and miR-451a as Potential Biomarkers in Invasive Breast Cancer and Their Clinicopathological Significance.

Zavesky L, Jandakova E, Weinberger V, Minar L, Kohoutova M, Tefr Faridova A Oncology. 2024; 103(2):112-127.

PMID: 39134012 PMC: 11793102. DOI: 10.1159/000540863.

The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target.

Sameti P, Tohidast M, Amini M, Bahojb Mahdavi S, Najafi S, Mokhtarzadeh A Cancer Cell Int. 2023; 23(1):134.

PMID: 37438760 PMC: 10337107. DOI: 10.1186/s12935-023-02972-0.

MicroRNA-183/96/182 cluster in immunity and autoimmunity.

Wang Z, Dai R, Ahmed S Front Immunol. 2023; 14:1134634.

PMID: 36891312 PMC: 9986322. DOI: 10.3389/fimmu.2023.1134634.

References

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S . MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2010; 102(3):522-9. DOI: 10.1111/j.1349-7006.2010.01816.x. View

Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L . MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 2011; 6(3):e18286. PMC: 3065473. DOI: 10.1371/journal.pone.0018286. View

Cho Y, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H . Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2010; 29(11):1424-30. PMC: 3082983. DOI: 10.1200/JCO.2010.28.5148. View

Mihelich B, Khramtsova E, Arva N, Vaishnav A, Johnson D, Giangreco A . miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem. 2011; 286(52):44503-11. PMC: 3247959. DOI: 10.1074/jbc.M111.262915. View

Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X . Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 2012; 180(6):2440-51. DOI: 10.1016/j.ajpath.2012.02.023. View

Merlo D, Ceppi M, Filiberti R, Bocchini V, Znaor A, Gamulin M . Breast cancer incidence trends in European women aged 20-39 years at diagnosis. Breast Cancer Res Treat. 2012; 134(1):363-70. DOI: 10.1007/s10549-012-2031-7. View

Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C . TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. J Clin Invest. 2012; 122(10):3563-78. PMC: 3589141. DOI: 10.1172/JCI62339. View

Xu D, He X, Chang Y, Xu C, Jiang X, Sun S . Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells. Oncol Rep. 2012; 29(2):653-61. DOI: 10.3892/or.2012.2138. View

10.

Tang H, Bian Y, Tu C, Wang Z, Yu Z, Liu Q . The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. Curr Cancer Drug Targets. 2012; 13(2):221-31. DOI: 10.2174/1568009611313020010. View

11.

Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai Z . microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013; 108(8):1659-67. PMC: 3668476. DOI: 10.1038/bjc.2013.125. View

12.

DeSantis C, Ma J, Bryan L, Jemal A . Breast cancer statistics, 2013. CA Cancer J Clin. 2013; 64(1):52-62. DOI: 10.3322/caac.21203. View

13.

Peng Q, Huang W, John-Baptiste A . Circulating microRNAs as biomarkers of retinal toxicity. J Appl Toxicol. 2013; 34(6):695-702. DOI: 10.1002/jat.2930. View

14.

Shalaby T, Fiaschetti G, Baumgartner M, Grotzer M . MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons. Int J Mol Sci. 2014; 15(11):21554-86. PMC: 4264241. DOI: 10.3390/ijms151121554. View

15.

Li P, Sheng C, Huang L, Zhang H, Huang L, Cheng Z . MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Res. 2014; 16(6):473. PMC: 4303194. DOI: 10.1186/s13058-014-0473-z. View

16.

Zhang Q, Ren W, Huang B, Yi L, Zhu H . MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells. Mol Med Rep. 2015; 12(1):668-74. DOI: 10.3892/mmr.2015.3376. View

17.

Dehkordy S, Hall K, Roach A, Rothman E, Dalton V, Carlos R . Trends in Breast Cancer Screening: Impact of U.S. Preventive Services Task Force Recommendations. Am J Prev Med. 2015; 49(3):419-22. PMC: 4546897. DOI: 10.1016/j.amepre.2015.02.017. View

18.

Tang H, Liu Q, Liu X, Ye F, Xie X, Xie X . Plasma miR-185 as a predictive biomarker for prognosis of malignant glioma. J Cancer Res Ther. 2015; 11(3):630-4. DOI: 10.4103/0973-1482.146121. View

19.

Song C, Liu L, Pei X, Liu X, Yang L, Ye F . miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget. 2015; 6(33):34968-78. PMC: 4741502. DOI: 10.18632/oncotarget.5198. View

20.

Weber M . New human and mouse microRNA genes found by homology search. FEBS J. 2005; 272(1):59-73. DOI: 10.1111/j.1432-1033.2004.04389.x. View